Eli Lilly agreed to acquire Bothell, Wash.-based Curevo Vaccine for up to $1.5 billion in cash. The deal centers on a next-generation shingles vaccine that reduced side effects by more than half in a Phase 2 study. Read More
Don't miss a headline!
Sign up for GeekWire's newsletters today.
Thanks for subscribing!
Check your inbox to confirm your subscription.
